Capsid proteins derived from Adeno-associated virus (AAV) are currently the most promising way of delivering therapeutic genes to patients’ cells. But because these capsid proteins belong to natural viruses, even the most widely used capsids are not optimal for disease treatment. There has been no systematic way to engineer new AAV capsids with improved functions, such as immune system evasion and precision delivery to target tissues - until now.
Using technologies pioneered in the lab of George Church at Harvard, Dyno’s AAV discovery platform enables, for the first time, multi-functional enhancement of AAV vector capsids for specific disease applications. By combining machine learning with next-generation DNA synthesis and high-throughput DNA sequencing we are designing optimal AAVs that fulfill the promise of genetic medicine.
Dyno is a VC-backed biotech startup located near Kendall Square in Cambridge, MA. We are looking for curious, collaborative, multi-disciplinary experts in gene therapy, synthetic biology, and machine learning to join our team.
Click on the links below to see the full posting and apply. Or contact firstname.lastname@example.org with any questions and general inquiries.